title: Targeting the Hedgehog pathway in cancer: can the spines be smoothened?
abstract: Aberrant Hedgehog (Hh) pathway signaling has been suggested to play a role in the development of multiple solid tumors and hematologic malignancies. GDC-0449 is a novel first-in-human, first-in-class smoothened (SMO) inhibitor, which has completed its phase I evaluation and achieved proof of concept in tumors with Hh pathway mutations.
authors.affiliation: Princess Margaret Hospital, Ontario Cancer Institute, University of Toronto, Toronto, Canada.
authors.forename: Laurie
authors.initials: L
authors.lastname: Ailles
authors.forename: Lillian L
authors.initials: LL
authors.lastname: Siu
mesh_terms: D000813:Anilides / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D053823:Hedgehog Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D006801:Humans; D008657:Metabolic Clearance Rate; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D009961:Orosomucoid / Q000378:metabolism; D011485:Protein Binding; D011725:Pyridines / Q000378:metabolism / Q000493:pharmacokinetics / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects*; D014157:Transcription Factors / Q000235:genetics; D016896:Treatment Outcome; D000071676:Zinc Finger Protein GLI1
chemical_list: D000813:Anilides; C400551:GLI1 protein, human; D053823:Hedgehog Proteins; C538724:HhAntag691; D009961:Orosomucoid; D011725:Pyridines; D014157:Transcription Factors; D000071676:Zinc Finger Protein GLI1